Literature DB >> 32294946

Immunization with Human Cytomegalovirus Core Fusion Machinery and Accessory Envelope Proteins Elicit Strong Synergistic Neutralizing Activities.

Xinle Cui1, Zhouhong Cao1, Shuishu Wang2, Stuart P Adler3, Michael A McVoy4, Clifford M Snapper1.   

Abstract

Human cytomegalovirus (HCMV) core fusion machinery proteins gB and gH/gL, and accessory proteins UL128/UL130/UL131A, are the key envelope proteins that mediate HCMV entry into and infection of host cells. To determine whether these HCMV envelope proteins could elicit neutralizing activities synergistically, we immunized rabbits with individual or various combinations of these proteins adsorbed to aluminum hydroxide mixed with CpG-ODN. We then analyzed serum neutralizing activities with multiple HCMV laboratory strains and clinical isolates. HCMV trimeric gB and gH/gL elicited high and moderate titers of HCMV neutralizing activity, respectively. HCMV gB in combination with gH/gL elicited up to 17-fold higher HCMV neutralizing activities compared to the sum of neutralizing activity elicited by the individual proteins analyzed with both fibroblasts and epithelial cells. HCMV gB+gH/gL+UL128/UL130/UL131A in combination increased the neutralizing activity up to 32-fold compared to the sum of neutralizing activities elicited by the individual proteins analyzed with epithelial cells. Adding UL128/UL130/UL131A to gB and gH/gL combination did not increase further the HCMV neutralizing activity analyzed with fibroblasts. These data suggest that the combination of HCMV core fusion machinery envelope proteins gB+gH/gL or the combination of gB and pentameric complex could be ideal vaccine candidates that would induce optimal immune responses against HCMV infection.

Entities:  

Keywords:  HCMV vaccine development; UL128/UL130/UL131A; congenital infection; core fusion machinery; envelope glycoprotein; gB; gH/gL; human cytomegalovirus; neutralizing antibody; solid organ and hematopoietic stem cell transplantation

Year:  2020        PMID: 32294946     DOI: 10.3390/vaccines8020179

Source DB:  PubMed          Journal:  Vaccines (Basel)        ISSN: 2076-393X


  4 in total

1.  Herpesvirus Vaccines.

Authors:  Stefano Petrini; Peter Maple
Journal:  Vaccines (Basel)       Date:  2022-04-18

2.  A conditionally replication-defective cytomegalovirus vaccine elicits potent and diverse functional monoclonal antibodies in a phase I clinical trial.

Authors:  Leike Li; Daniel C Freed; Yaping Liu; Fengsheng Li; Diane F Barrett; Wei Xiong; Xiaohua Ye; Stuart P Adler; Richard E Rupp; Dai Wang; Ningyan Zhang; Tong-Ming Fu; Zhiqiang An
Journal:  NPJ Vaccines       Date:  2021-06-02       Impact factor: 7.344

3.  Immunization with Epstein-Barr Virus Core Fusion Machinery Envelope Proteins Elicit High Titers of Neutralizing Activities and Protect Humanized Mice from Lethal Dose EBV Challenge.

Authors:  Xinle Cui; Zhouhong Cao; Yuriko Ishikawa; Sara Cui; Ken-Ichi Imadome; Clifford M Snapper
Journal:  Vaccines (Basel)       Date:  2021-03-19

Review 4.  Epstein Barr Virus: Development of Vaccines and Immune Cell Therapy for EBV-Associated Diseases.

Authors:  Xinle Cui; Clifford M Snapper
Journal:  Front Immunol       Date:  2021-10-08       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.